Cost-Effectiveness Analysis of Lu-177-PSMA-617
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant [...]
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant [...]
Novartis has obtained US Food and Drug Administration (FDA) marketing [...]
Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients [...]